Phase 1 N=61 BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Neoplasms
Primary: Maximum Tolerated Dose — 0; 0; 0; 0 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=7 BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Neoplasms
Primary: Individual Time Course Profiles of 14C-radioactivity in Whole Blood and Plasma: Cmax of 14C Labelled Volasertib — 1746; 1150 nmol/L
Phase 1 N=33 A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1 — 9.148; 18.18; 25.23; 38.32…
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 1 N=16 Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
Chronic Myelomonocytic Leukemia · Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk…
Phase 1 N=100 A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
Dengue Fever
Primary: Number of Subjects With Adverse Events Within the 28 Day Follow-up — 10; 9; 10; 14 Participants
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Phase 1 N=24 Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of…
Phase 1 N=12 A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
Healthy
Primary: Plasma AUCinf for PF-06463922 Given Alone and With Rifampin — 8766; 1299 nanogram (ng)*hr/ millilitre (mL)
Phase 1 N=27 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Asthma
Primary: Number of Participants Who Experienced One or More Adverse Events — 9; 3 Participants
Phase 1 N=72 A Study of LY3025876 in Participants With Diabetes
Type 2 Diabetes Mellitus
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 1 N=30 A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma
Asthma
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1). — 0.225; 0.400; 0.108; 0.170 Liters — p=<0.0001
Phase 1 N=50 A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Shigellosis
Primary: Number of Subjects With Solicited Local Reaction After Any Vaccination — 8; 9; 8; 8 Participants
Phase 1 N=60 A Study of LY2541546 in Healthy Postmenopausal Women
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 1 N=35 A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites — 133; 109; 83.9; 156 nanograms per milliliter (ng/mL)